ArticleBlood advances2022
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
David Qualls et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it
ArticleBlood advances2022
David Qualls et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.